Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics


Alexion Pharmaceuticals, Inc. (ALXN): $153.65

-0.84 (-0.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALXN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 318

in industry

ALXN Stock Summary

  • With a market capitalization of $33,758,711,002, Alexion Pharmaceuticals Inc has a greater market value than 92.71% of US stocks.
  • ALXN's current price/earnings ratio is 55.95, which is higher than 80.13% of US stocks with positive earnings.
  • Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 15.62% of US stocks have a lower such ratio.
  • If you're looking for stocks that are quantitatively similar to Alexion Pharmaceuticals Inc, a group of peers worth examining would be JAZZ, HPE, EXPE, FSLR, and COHR.
  • Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to www.alexion.com.

ALXN Stock Price Chart Interactive Chart >

Price chart for ALXN

ALXN Price/Volume Stats

Current price $153.65 52-week high $162.60
Prev. close $154.49 52-week low $72.67
Day low $152.95 Volume 2,372,300
Day high $155.48 Avg. volume 2,844,386
50-day MA $156.18 Dividend yield N/A
200-day MA $123.97 Market Cap 33.78B

Alexion Pharmaceuticals, Inc. (ALXN) Company Bio


Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.

ALXN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$153.65$403.08 162%

We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 72th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 163.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Alexion Pharmaceuticals Inc, consider:

  • The company has produced more trailing twelve month cash flow than 87.77% of its sector Healthcare.
  • The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately only 22.82% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Alexion Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%157%
1%160%
2%162%
3%165%
4%167%
5%170%

ANTM, CVS, CSTL, HCSG, and CAH can be thought of as valuation peers to ALXN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


ALXN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALXN Latest Social Stream


Loading social stream, please wait...

View Full ALXN Social Stream

Latest ALXN News From Around the Web

Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.

BioCryst Short-Sellers Lose Control

The Company BioCryst (NASDAQ:BCRX) develops novel, oral and small molecules that inhibit enzymes playing a key role in biological pathways of rare diseases. Biocryst has built a world-class sales team to launch Orladeyo in the US and EU. Biocryst has signed a licensing agreement with Torii to launch the product...

Tom Payne on Seeking Alpha | February 22, 2021

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

Business Wire | February 22, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - MDCA, VIE, CLGX, ALXN, TCF

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | February 20, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | February 19, 2021

Top Merger Stocks Held By Fund Managers, Mid-Q1 2021

Stock prices have risen more in the past 11 months than anyone could have anticipated. And as you might expect, many companies have been using their inflated stocks to buy other companies. In fact, only two of the top ten deals I have complied from the 13F filings are pure...

Special Situations and Arbs on Seeking Alpha | February 17, 2021

Read More 'ALXN' Stories Here

ALXN Price Returns

1-mo -1.31%
3-mo 24.08%
6-mo 43.61%
1-year 66.85%
3-year 29.84%
5-year 9.62%
YTD -1.66%
2020 44.47%
2019 11.08%
2018 -18.59%
2017 -2.26%
2016 -35.86%

Continue Researching ALXN

Want to see what other sources are saying about Alexion Pharmaceuticals Inc's financials and stock price? Try the links below:

Alexion Pharmaceuticals Inc (ALXN) Stock Price | Nasdaq
Alexion Pharmaceuticals Inc (ALXN) Stock Quote, History and News - Yahoo Finance
Alexion Pharmaceuticals Inc (ALXN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8602 seconds.